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Objectives: The limited information available on thoracoscopic pulmonary vein isolation combined with gangli-
onated plexi ablation and the lack of studies regarding its effect on quality of life and physical capacity urged us to
study its acute and long-term results in patients with atrial fibrillation.
Methods: Forty-three patients (mean age 57.1 years) with symptomatic atrial fibrillation referred for thoraco-
scopic off-pump epicardial pulmonary vein isolation and ganglionated plexi ablation using radiofrequency energy
were included.
Results: The physical capacity improved significantly at 6-month follow-up compared with baseline (mean 
standard deviation, 165.2  65 Watt versus 155.9  57 Watt, P ¼ .02). Quality of life (Short Form-36 health
survey) significantly improved 12 months after surgery compared with baseline in all subscales except for bodily
pain. The symptom severity questionnaire score decreased significantly from mean 15.2  4.0 points to 10.7 
4.8 points (P ¼ .02). Overall, 25 of 33 patients (76%) followed up for 12 months had no symptomatic atrial fi-
brillation recurrences or atrial fibrillation episodes on 24-hour Holter recordings. The corresponding figures were
79% (19/24) for patients with paroxysmal atrial fibrillation, 100% (2/2) for persistent atrial fibrillation, and 57%
(4/7) for permanent atrial fibrillation. The most common complication was bleeding events (9%) during pulmo-
nary vein dissection.
Conclusions: Epicardial off-pump pulmonary vein isolation combined with ganglionated plexi ablation im-
proved quality of life, symptoms, and exercise capacity and therefore may be considered for patients with atrial
fibrillation who fail endocardial pulmonary vein ablation or as a first-line procedure if left atrial appendage ex-
clusion is warranted.
Bagge et al Evolving TechnologyAlthough transvenous radiofrequency (RF) atrial fibrillation
(AF) ablation is reported to eliminate AF in a high propor-
tion of cases,1,2 pulmonary vein (PV) reconduction is still
a recognized problem, possibly reflecting difficulties in
achieving transmural lesions.3 Alternative approaches,
such as thoracoscopic epicardial PV isolation, therefore
have evolved. This technique was recently reported to result
in AF elimination in 80% to 91% of the patients.4,5 Further-
more, it was recently suggested that ganglionated plexi (GP)
ablation combined with epicardial PV isolation and left atrial
appendage (LAA) exclusion may increase the rate of free-
dom from AF.6-10 Limited information is, however, avail-
able about the long-term outcome of such procedure, and
its effects on quality of life (QoL), symptoms, and physical
capacity are lacking. The purpose of the present study there-
fore was to describe the acute and long-term results of com-
bined PV isolation and GP ablation for the treatment of AF
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and freedom from AF.
METHODS
Patients and Investigations
A total of 43 patients were referred for epicardial PV isolation combined
with GP ablation between November 2005 and March 2008 (Table 1). Pa-
tients who had failed at least 1 class I (86%) or III (93%) antiarrhythmic
agent for symptomatic paroxysmal, persistent, or permanent AF were in-
cluded. Eighteen (42%) patients had previously failed a transvenous endo-
cardial PV isolation, and 11 patients (26%) previously had an atrial flutter
ablation. Six patients (14%) had a permanent pacemaker preoperatively.
All patients were treated with warfarin with the international normalized
ratio level targeted between 2 and 3 for at least 1 month prior to the proce-
dure. Thrombus formation in the LAA was excluded by transesophageal
echocardiography the day before the operation. Warfarin was replaced by
low-molecular-weight heparin when the international normalized ratio
value was less than 2 before surgery but was resumed on the evening before
operation. It was then withdrawn 3 months after the operation except for pa-
tients with a history of stroke or transient ischemic attack or with CHADS2
score above 2. Heparin (5000 IU) was administrated intravenously during
surgery. Antiarrhythmic drugs (AADs) were continued for at least 3 months
after surgery, at which time they were withdrawn in patients who remained
in sinus rhythm. Amiodarone was prescribed if AF recurred more than once
during the first 3 months postoperatively.
The clinical evaluation at baseline included a symptom severity ques-
tionnaire (SSQ), Study Short Form-36 questionnaire for QoL,11 physical
examination, 12-lead electrocardiogram (ECG), 2-dimensional echocardi-
ography, exercise bicycle test, coronary angiography (if age above 50 years
E
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TAbbreviations and Acronyms
AAD ¼ antiarrhythmic drug
AF ¼ atrial fibrillation
CT ¼ contrast tomography
ECG ¼ electrocardiogram
GP ¼ ganglionated plexi
LAA ¼ left atrial appendage
PV ¼ pulmonary vein
QoL ¼ quality of life
RF ¼ radiofrequency
SSQ ¼ symptom severity questionnaire
or if symptoms suggested ischemic heart disease), 24-hour Holter recording,
and contrast tomography (CT) for PV anatomy. Coronary artery disease was
defined as previous myocardial infarction, coronary artery revasculariza-
tion, or documented significant coronary artery stenosis on angiography.
The 5 variables in the SSQ (palpitations, fatigue, dizziness, lack of energy,
dyspnea) were each scored with regard to severity on a 5-grade scale.2 The
patients were followed with regard to symptoms of AF and 12-lead ECG at
3, 6, and 12 months after the surgery. The exercise bicycle test, echocardi-
ography, CT (to exclude PV stenosis), 24-hour Holter recording, SSQ, and
Short Form-36 were evaluated after 6 months, and the latter three (24-hour
Holter recording, SSQ, and Short Form-36) were repeated at 12-month fol-
low-up. A successful outcome was defined as no documented symptomatic AF
episodes or left atrial tachycardias after 12 months of follow-up, excluding the
initial 3 months postoperatively, according to 12-lead ECG, 24-hour Holter re-
cording, and spot ECG recorded when symptoms dictated. Patients gave their
consent to the study, which was approved by the local Ethics Review Board.
Procedural Technique
The thoracoscopic off-pump procedure included epicardial PV isolation,
left atrial GP ablation, division of the ligament of Marshall, and left atrial
appendectomy. General anesthesia was administered with a double-lumen
endotracheal tube. The procedure started on the right side in all but 1 patient
to ensure that electrical isolation could be completed for all veins, in case the
excision of the LAA would result in any complication.
With the patient in a left lateral recumbent position and with the right
lung deflated, the procedure was initiated by inserting the thoracoscope
(Storz, Tuttlingen, Germany) at the level of the xiphoid process. A small
thoracic incision was made in the third intercostal space to approach the
right PVs. Through the incision, the pericardium was opened anterior and
parallel to the phrenicus nerve from the superior vena cava down to the in-
ferior vena cava. Blunt dissection around the PVs was performed with
a lighted dissector (first-generation device, Atricure, West Chester, Ohio)
entering into the oblique sinus and passing out above the superior PV.
The dissector was then replaced by a rubber band.
To identify predominantly vagal GP, high-frequency electrical stimula-
tion (800 pulses per minute, pulse-width 9.9 ms) was applied at 10 sites ac-
cording to a map (Figure 1, A) adapted from Warren Jackman, University of
Oklahoma. A positive response was defined as a bradycardia with a doubling
of the R-R interval. The rubber band was then used to introduce the ablation
clamp (Atricure) around the PV pair. PV conduction prior to ablation was
assessed for each PV pair. The clamp was closed well proximal to the con-
fluence of the veins where after RF ablation was applied according to an al-
gorithm that automatically stopped the ablation when the impedance change
indicated that a transmural lesion was achieved between the jaws. Conduc-
tion block was then confirmed by pacing or, if AF was present, by the ab-
sence of fibrillation potentials on the distal or PV side of the ablation line.
In case conduction block was not achieved after the first 3 consecutive ap-1266 The Journal of Thoracic and Cardiovascular Suplications, 1 or 2 additional RF applications were given until PV conduction
block occurred. The high-frequency stimulation scheme (Figure 1, A) was
then repeated, and if GP activity was still present, it was abolished by elec-
trocautery or by an RF ablation pen (Atricure), until no vagal response could
be provoked. A thoracic drain was inserted, the lung was inflated, and the
incisions closed.
The patient was then repositioned in a right lateral recumbent position
and the procedure repeated as described above to approach the left PVs
for isolation and GP ablation. If a ligament of Marshall could be identified,
it was divided. Finally, the LAA was excised using a stapler (Autosuture,
United States Surgical, Norwalk, Conn), if judged feasible and safe (absence
of a wide base or thin wall). Intercostal analgesic blockade was given on
both the right and left sides.
Statistical Analysis
Continuous variables, when appropriate, were compared with the use of
Student t test or otherwise Mann–Whitney U test. Tukey HSD test was used
for the comparison of QoL. Wilcoxon matched-paired test or, when appro-
priate, the analysis of variance test was used for the evaluation of symptom
scores. All P values were 2-sided. Results are expressed as mean  1
standard deviation, unless otherwise stated.
The authors had full access to the data and take responsibility for its
integrity. All authors have read and agree to the manuscript as written.
RESULTS
The results are based on the 42 patients in whom PV iso-
lation could be performed. One patient was excluded because
of premature termination of the procedure before PV isola-
tion due to bleeding from the right PV during dissection.
Isolation of all PVs was completed in all but 5 of the re-
maining 42 patients and required 3 to 4 applications (median
3) on the right side and 2 to 5 applications (median 3) on the
left side. Electrical isolation was not achieved on the left side
in 1 patient despite 7 applications and not on the right side
in another patient despite 11 applications. In 2 cases, PV
TABLE 1. Patient demographics
Characteristics Results
Age (y), median (range) 58 (36–71)
Sex, male 29 (67)
History of AF (y), median (range) 7 (1–22)
Paroxysmal AF 28 (65)
Persistent AF 6 (14)
Permanent AF 9 (21)
Lone AF 21 (49)
Hypertension 13 (30)
Cerebral stroke/TIA/neurologic deficit 8 (19)
Diabetes mellitus 1 (2)
Coronary artery disease 3 (7)
Valvular heart disease 4 (9)
Heart failure or cardiomyopathy 6 (14)
Asthma 4 (9)
Sleep apnea syndrome 2 (5)
LVEF<50 6 (14)
LAd, cm, median (range) 4.5 (2.6–6.2)
Figures denote numbers and percentages in parentheses unless otherwise stated. AF,
atrial fibrillation; TIA, transient ischemic attack; LVEF, left ventricular ejection frac-
tion; LAd, left atrial diameter.rgery c May 2009
Bagge et al Evolving TechnologyFIGURE 1. A, Sites of high-frequency stimulation of ganglionated plexi (GP). In every patient 10 sites on the right side (R1–R10) and 10 on the left side
(L1–L10) of the left atrium were mapped. RSPV, Right superior pulmonary vein; RIPV, right inferior pulmonary vein; LSPV, left superior pulmonary vein;
LIPV, left inferior pulmonary vein; LA, left atrium; LAA, left atrium appendage; AV, atrioventricular; R, right; L, left. B, Results of epicardial GP mapping.
High-frequency stimulation map showing distribution of active GP sites displayed as percentages as well as by grayscale.E
Tisolation could not be completed on the right side because of
either a rift of 1 of the PVs or a rift of the tissue around the
right inferior PV and the inferior vena cava during dissec-
tion. In the last case, a thrombus in the LAA disclosed by
the transesophageal echocardiography during surgery pre-
cluded PV isolation on the left side. PV reconduction was
confirmed for all vein pairs tested in the patients with a prior
catheter ablation procedure.
Vagal GP activity was present in all but 2 patients at base-
line before the PV isolation. Active GP at baseline were iden-
tified on both the left and right side in 23 of 42 (55%) patients
but on the right side only in 17 of 42 (40%) patients. There
were significantly more active GP sites on the right than on
the left side (4.0 2.4 vs 1.4 1.7, P<.001), and the great-
est concentrations of vagal GP activity were found around the
Waterton’s groove on the right side and the ligament of
Marshall on the left side (Figure 1, B). In 1 patient in
whom the operation started on the left side, GP activity could
only be demonstrated on the right side at baseline.The Journal of Thoracic and CPatients who previously had transvenous catheter-based
AF ablation had significantly fewer active vagal GP sites
(mean 4.0  2.2) at baseline than those who had not
(mean 6.4  3.5, P¼ .01). Vagal GP activity was present
in all but 1 of the patients who had previous AF ablation.
The number of active vagal GP sites in patients with parox-
ysmal AF was not significantly different from those in
patients with persistent or permanent AF (mean 4.9  3.1
vs 6.2  2.0, P ¼ .23). Complete elimination of all active
GP sites failed in 16 of the 42 patients (38%), and the max-
imum number of active GP sites that could not be abolished
was 4 sites in 1 patient. The ligament of Marshall was iden-
tified and divided in 40 patients (95%), and the LAA was
excluded in 32 of the 42 patients (76%). The LAA could
not be extirpated because of a wide base in 6 patients and
because of poor accessibility in another 3 patients. A throm-
bus precluded LAA exclusion in another patient.
The surgical procedure time ranged from 185 to 410
minutes (median 227.5 minutes). The hospital stay rangedardiovascular Surgery c Volume 137, Number 5 1267
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TFIGURE 2. Comparison of quality of life assessed by the Short Form-36 questionnaire for QoL. A, Baseline (n ¼ 42) versus 12 months following surgery
(n ¼ 33). Error bars show 95% confidence limits of the mean.:, Baseline;-, 12-month follow-up; PF, physical functioning; RP, role limitation due to
physical problems;BP, bodily pain;GH, general health; VT, vitality; SF, social functioning;RE, role limitation due to emotional problems;MH, mental health.
PF: P ¼ .0019; RP: P ¼ .0078; BP: P ¼ .39; GH: P ¼ .0070; VT: P ¼ .00014; SF: P ¼ .00014; RE: P ¼ .00059; MH: P ¼ .00036. B, Twelve months after
surgery (n ¼ 33) versus the general Swedish population. -, 12-month follow-up; B, Swedish general population. PF: P ¼ .038; RP: P ¼ .0023; BP:
P ¼ .78; GH: P ¼ .0065; VT: P ¼ .046; SF: P ¼ .096; RE: P ¼ .080; MH: P ¼ 0.53.from 6 to 34 days (median 11 days) including 2 to 17 days
(median 4 days) at the intensive care unit.
Follow-up
Forty-one of the 42 patients who had PV isolation were
followed after surgery. One patient living abroad was
excluded from follow-up.
Twenty-five of the 33 patients (76%) who had completed
the 12-month follow-up schedule were free from AF
episodes according to 12-lead ECG, 24- to 48-hour Holter-
recording, and spot ECG at the time of symptoms. When
success rate was related to the type of AF, the corresponding
figures were 79% (19 of 24) for patients with paroxysmal
AF, 100% (2 of 2) for those with persistent AF, and 57%
(4 of 7) for patients with permanent AF, although the differ-
ences did not reach statistical significance. The rate of free-
dom from AF was 69% in patients who had a previous
catheter-based AF ablation compared with 81% in those
who had not (P ¼ .46). None of the 25 patients who were
free from clinical recurrent AF episodes had asymptomatic
episodes of AF on Holter recordings, but in 5 of them the
recording showed supraventricular extrasystoles or nonsus-
tained regular supraventricular tachycardia. No patient
suffered from left atrial tachycardias.
Among the 25 patients clinically free from AF at
12-month follow-up, 8 (32%) were still on AADs and 6
were still on warfarin related to earlier stroke/transient ische-
mic attack/thromboembolic event in 4 patients and for
unknown reason in 2 patients.
Of the remaining 9 patients followed up for 12 months, 1
patient missed the 24-hour Holter recording related to cancer1268 The Journal of Thoracic and Cardiovascular Streatment but had no clinical or symptomatic AF recur-
rences, 6 patients had paroxysmal AF, and 2 had permanent
AF. Two other patients had tricuspid isthmus ablation for
atrial flutter. Another 2 patients required pacemaker implan-
tation for chronotropic incompetence and bradycardia
related to medication with beta-blocking agents 18 months
and 8 months after surgery, respectively.
Of the remaining 7 patients who had not reached 12
months of follow-up, 3 of 4 patients followed up for 6
months and 2 out of 3 patients who completed 3 months
of follow-up had no documented episodes of AF.
The number of active GP sites at baseline did not differ
between patients who remained free from AF (5.1  3.3)
and those with AF recurrence at last follow-up (5.2  1.9,
P ¼ .864).
Health-related QoL was significantly improved at 6 and 12
months on all scales except for bodily pain, as compared with
baseline before surgery (Figure 2, A). Physical functioning
and role limitation due to physical problems was not signif-
icantly improved until 12-month follow-up. At 12-month fol-
low-up, QoL reached the values of a general Swedish
population for 4 of the scales (Figure 2, B). The QoL prior
to surgery was significantly lower than for the Swedish
general population, with the exception of bodily pain.
Overall, symptom severity scores improved significantly
at 12 months after surgery (10.7  4.8 points) compared
with baseline (15.2  4.0 points, P ¼ .02). All symptoms
except for dizziness and palpitations improved at 12-month
follow-up as compared with baseline (Table 2). Patients who
remained in sinus rhythm had significantly lower symptom
severity score at 12-month follow-up (mean 10.2  5.0urgery c May 2009
Bagge et al Evolving TechnologyTABLE 2. Symptoms at baseline and at 6 and 12 months after the surgery
6 mo (n ¼ 17) 12 mo (n ¼ 33)
SSQ variable Baseline (n ¼ 37), mean (95% CL) Mean (95% CL) P value* Mean (95% CL) P valuey
Palpitations 2.6 (2.1–3.1) 1.8 (1.1–2.4) .09 2.2 (1.7–2.6) .28
Fatigue 3.6 (3.2–4.1) 2.2 (1.5–3.0) .018 2.2 (1.7–2.7) .004
Dizziness 2.1 (1.7–2.5) 1.9 (1.2–2.7) .35 1.8 (1.4–2.3) .67
Lack of energy 3.9 (3.5–4.3) 2.5 (1.6–3.4) .07 2.5 (2.0–3.0) .006
Dyspnea 2.9 (2.5–3.4) 1.9 (1.2–2.7) .07 2.0 (1.5–2.4) <.001
CL, Confidence limit; SSQ, symptom severity questionnaire. *SSQ score at 6 mo vs baseline. ySSQ score at 12 mo vs baseline.E
Tpoints) compared with baseline (mean 15.8  4.7 points,
P ¼ .036), but only dyspnea (P ¼ .018) and fatigue (P ¼
.015) improved significantly. In patients with recurrences
of AF, the symptom severity score did not differ between
12-month follow-up and baseline (mean 13.4  3.2 points
vs 15.0  1.6 points, P ¼ .42), and nor did the separate
symptoms.
The physical capacity on exercise test was significantly
improved at 6 months compared with baseline (165.2 
64.8 Watt vs 155.9  56.7 Watt, P ¼ .02).
Learning Curve
The first 40 procedures were divided into groups of 10 to
analyze the learning curve with regard to procedure time and
bleeding events (Figure 3). The procedure time was signifi-
cantly reduced from 274 42 minutes for the first 10 proce-
dures to 224  26 minutes for the last 10 procedures
(P ¼ .0070).
Complications
There were no perioperative or late deaths after surgery.
Major bleeding, defined as bleeding requiring transfusion or
surgical intervention and/or leading to treatment cessation,
occurred in 6 patients (Table 3). The reasons for bleeding
FIGURE 3. Learning curve with procedure time averaged per group of 10
consecutive patients. *The time at which major bleeding occurred.The Journal of Thoracic and Cawere rupture of the staple line when the LAA was extirpated
(1), rift of a right PV (2), rift of the tissue around the right
inferior PV and the inferior vena cava (1), rift of the pulmo-
nary artery during dissection (1), and bleeding from an inter-
costal artery (1), which required reoperation twice. In 4 of
these cases, an extension of the incision was made, and in
2, the heart–lung machine was required. In the first patient
requiring heart–lung machine, the femoral nerve was dam-
aged during the acute dissection for cannulation in the groin,
and in the other, the operation could not be completed. Three
of these patients needed blood transfusions. The time at which
bleeding events occurred is depicted in the learning curve
(Figure 3). One patient with permanent AF suffered from
a stroke 2 days after the operation. Warfarin had been discon-
tinued 4 days before the surgery but by mistake was not
replaced by low-molecular-weight heparin until the day
before operation. No patient developed PV stenosis according
to CT performed 5 to 12 months after surgery in 31 patients.
DISCUSSION
The new minimally invasive epicardial procedure that
combines PV isolation and GP ablation has revealed some
impressive success rates in eliminating AF,6-10 ranging
between 74.2% and 93% at 6-month follow-up6,10 and
75% to 90% at mean 16.6 to 17 months follow-up.7,9
TABLE 3. Complications after surgery
Complication n (%)
Perioperative* (n ¼ 43)
Hemorrhage 6 (14)
Pleural effusion/hemothorax 2 (5)
Ventricular tachycardia 1 (2)
Transient confusion 1 (2)
Rib fracture 1 (2)
Infections 4 (9)
Ischemic stroke 1 (2)
Postpericardiotomy syndrome 1 (2)
Latey (n ¼ 42)
Postpericardiotomy syndrome 1 (2)
Infections 2 (5)
Esophagitis and gastritis 1 (2)
Incisional hernia 1 (2)
*During hospitalization. yUp to 12 mo after hospitalization.rdiovascular Surgery c Volume 137, Number 5 1269
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TDivergent patient selections, variation in lesion sets used,
and different study designs and follow-ups, however,
make it difficult to compare the present study with others.
In the present study, 75.8% of the patients were clinically
free from AF, which is a lower success rate than the 93%
reported by Mehall et al.6 The higher success rate in that
study may be explained by their selection of patients with
lone AF only and their shorter follow-up of 6 months, which
notably was only available for 15 of their 26 patients. The
other study reporting a higher success rate (90%) only in-
cluded 20 patients, of whom only 10% had previous catheter
ablation compared with our 42%, and of whom 80% had
paroxysmal AF compared with 65% in our study.9 It is
well known that PV isolation is more effective in patients
with paroxysmal AF than in those with persistent AF,1 and
patients with previously failed transvenous AF ablation are
likely more difficult to treat, as was indicated in our study.
Our results are more in accordance with the two other stud-
ies,7,10 although one study7 included only 20 patients and the
other10 was limited by their short follow-up and in that
AADs had not been discontinued in over 42% of their 66
patients. Furthermore, their autotriggered event monitor,
including only 15-second rhythm strip for calculation of
AF burden, is limited by the lack of validity studies. Hence,
considering number and selection of patients and time of
follow-up, the outcome of the present study compares favor-
ably with previous studies, even though asymptomatic AF
episodes could not be excluded because we did not have
access to continuous rhythm monitoring.
Our finding that vagal GP activity is far more prevalent on
the right than on the left side as well as around the ligament
of Marshall and Waterston’s groove has been reported by
others.6,7,10 One cannot exclude, however, that the preced-
ing right-sided PV isolation may have eliminated some of
the active GP sites present on the left side. The importance
of GP ablation for an improved outcome of the procedure,
however, has not yet been proven. One retrospective study
reported that vagal denervation enhances the long-term ben-
efit after circumferential ablation for paroxysmal AF,12 and
another prospective but nonrandomized study suggested that
the addition of GP ablation to conventional PV antrum iso-
lation may increase the success rate from 70% to 91%.13
Others claiming the opposite reported that freedom from
AF recurrences was more common after circumferential
PV ablation (63%) than after anatomic GP ablation as
a stand-alone treatment (26%).14 Moreover, epicardial fat
pad ablation, comparable with GP ablation, did not suppress
AF induction in an experimental study.15
Our novel findings that both symptoms and QoL
improved after the procedure are of great importance as
the main clinical indication for the procedure is to reduce
symptoms and increase QoL. The symptom severity scores
recorded at baseline in our study were comparable with
those reported in a previous randomized trial of transvenous1270 The Journal of Thoracic and Cardiovascular Sucircumferential PV ablation for highly symptomatic long-
standing persistent AF,2 indicating that our patients were
as highly symptomatic. The possibility of a placebo effect
after the surgical procedure explaining the differences in
symptoms and QoL between baseline and 12 months is con-
tradicted by our observation that the symptom severity score
only improved in the patients who remained in sinus rhythm
and not in the patients with AF recurrences. The finding that
palpitations were not significantly reduced even in patients
with sinus rhythm may be related to the presence of extra
beats, revealed on Holter recordings. The improved physical
capacity following the procedure in our study further indi-
cates that there was not only a subjective but also an objec-
tive improvement after surgery.
Major bleeding was the most common complication in
our study, which is in accordance with the 4 other studies.
Our bleeding rate of 14% was higher than that reported in
2 other studies (2.7%–4.8%)7,10 but comparable to the
15.0% in another study.9 According to our experience, the
most vulnerable moment is the dissection around the PVs,
accounting for 4 of the 6 bleeding events, which did not
seem to follow the learning curve (Figure 3). Although
only 1 bleeding event was related to the exclusion of the
LAA, a significant portion of patients (23.8%) were judged
to be at too high risk for such procedure, indicating that this
may also be a critical moment. This is supported by the
report of 1 death due to tearing of the base of the LAA.10
An advantage with the epicardial approach is the possibility
of LAA exclusion, for an anticipated reduced risk of future
thromboembolic events, which is not yet feasible with the
transvenous AF ablation technique.16 The potentially life-
threatening complications associated with transvenous AF
ablation, such as PV stenosis, tamponade, and left atrial-
esophageal fistula,16,17 seem to be of no major concern using
the epicardial approach, as to our best knowledge, none of
these complications have been reported. However, 1 case
of pulmonary embolism requiring rehospitalization has
been reported after the procedure.18 This less invasive proce-
dure may avoid the use of cardiopulmonary bypass and most
likely carries a lower risk for pacemaker implantation. These
are possible advantages of this procedure over a traditional
cut-and-sew maze procedure.
In conclusion, off-pump epicardial PV isolation com-
bined with GP ablation is a relatively safe and efficacious
treatment and may therefore be considered for patients
with drug-resistant paroxysmal or persistent AF who failed
endocardial PV ablation or as a first-line procedure if LAA
exclusion is warranted. Further studies are, however, neces-
sary to reveal the additive value of GP ablation.
References
1. Stabile G, Bertaglia E, Senatore G, De Simone A, Zoppo F, Donnici G, et al. Cath-
eter ablation treatment in patients with drug-refractory atrial fibrillation: a prospec-
tive, multi-centre, randomized, controlled study (Catheter Ablation For The Cure
Of Atrial Fibrillation Study). Eur Heart J. 2006;27:216-21.rgery c May 2009
Bagge et al Evolving Technology2. Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi F Jr, et al. Circumferential
pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med. 2006;354:
934-41.
3. Chen ML, Yang B, Xu DJ, Zou JG, Shan QJ, Chen C, et al. [Electrophysiological
findings and ablation strategies in patients with atrial tachyarrhythmias after left
atrial circumferential ablation in the treatment of atrial fibrillation]. Zhonghua
Xin Xue Guan Bing Za Zhi. 2007;35:119-22.
4. Wolf RK, Schneeberger EW, Osterday R, Miller D, Merrill W, Flege JB Jr, et al.
Video-assisted bilateral pulmonary vein isolation and left atrial appendage exclu-
sion for atrial fibrillation. J Thorac Cardiovasc Surg. 2005;130:797-802.
5. Sagbas E, Akpinar B, Sanisoglu I, Caynak B, Tamtekin B, Oral K, et al. Video-
assisted bilateral epicardial pulmonary vein isolation for the treatment of lone
atrial fibrillation. Ann Thorac Surg. 2007;83:1724-30.
6. Mehall JR, Kohut RM Jr, Schneeberger EW, Taketani T, Merrill WH, Wolf RK.
Intraoperative epicardial electrophysiologic mapping and isolation of autonomic
ganglionic plexi. Ann Thorac Surg. 2007;83:538-41.
7. McClelland JH, Duke D, Reddy R. Preliminary results of a limited thoracotomy: new
approach to treat atrial fibrillation. J Cardiovasc Electrophysiol. 2007;18:1289-95.
8. Edgerton JR, Jackman WM, Mack MJ. Minimally invasive pulmonary vein iso-
lation and partial autonomic denervation for surgical treatment of atrial fibrilla-
tion. J Interv Card Electrophysiol. 2007;20:89-93.
9. Matsutani N, Takase B, Ozeki Y, Maehara T, Lee R. Minimally invasive cardio-
thoracic surgery for atrial fibrillation: a combined Japan-US experience. Circ J.
2008;72:434-6.
10. Edgerton JR, Edgerton ZJ, Weaver T, Reed K, Prince S, Herbert MA, et al. Min-
imally invasive pulmonary vein isolation and partial autonomic denervation forThe Journal of Thoracic and Csurgical treatment of atrial fibrillation. Ann Thorac Surg. 2008;86:35-8; discus-
sion 39.
11. Lonnerholm S, Blomstrom P, Nilsson L, Oxelbark S, Jideus L, Blomstrom-
Lundqvist C. Effects of the maze operation on health-related quality of life in
patients with atrial fibrillation. Circulation. 2000;101:2607-11.
12. Pappone C, Santinelli V, Manguso F, Vicedomini G, Gugliotta F, Augello G, et al.
Pulmonary vein denervation enhances long-term benefit after circumferential
ablation for paroxysmal atrial fibrillation. Circulation. 2004;109:327-34.
13. Scherlag BJ, Nakagawa H, Jackman WM, Yamanashi WS, Patterson E, Po S, et al.
Electrical stimulation to identify neural elements on the heart: their role in atrial
fibrillation. J Interv Card Electrophysiol. 2005;13(Suppl 1):37-42.
14. Katritsis D, Giazitzoglou E, Sougiannis D, Goumas N, Paxinos G, Camm AJ. An-
atomic approach for ganglionic plexi ablation in patients with paroxysmal atrial
fibrillation. Am J Cardiol. 2008;102:330-4.
15. Oh S, Zhang Y, Bibevski S, Marrouche NF, Natale A, Mazgalev TN. Vagal de-
nervation and atrial fibrillation inducibility: epicardial fat pad ablation does not
have long-term effects. Heart Rhythm. 2006;3:701-8.
16. Bertaglia E, Zoppo F, Tondo C, Colella A, Mantovan R, Senatore G, et al. Early
complications of pulmonary vein catheter ablation for atrial fibrillation: a multi-
center prospective registry on procedural safety. Heart Rhythm. 2007;4:1265-71.
17. Pappone C, Oral H, Santinelli V, Vicedomini G, Lang CC, Manguso F, et al.
Atrio-esophageal fistula as a complication of percutaneous transcatheter ablation
of atrial fibrillation. Circulation. 2004;109:2724-6.
18. Wudel JH, Chaudhuri P, Hiller JJ. Video-assisted epicardial ablation and left atrial
appendage exclusion for atrial fibrillation: extended follow-up. Ann Thorac Surg.
2008;85:34-8.ardiovascular Surgery c Volume 137, Number 5 1271
E
T
